Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.

[1]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[2]  M. Colombo,et al.  A meta‐analysis of single HCV‐untreated arm of studies evaluating outcomes after curative treatments of HCV‐related hepatocellular carcinoma , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[3]  A. Gasbarrini,et al.  Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[4]  W. Kim,et al.  Reduction in liver transplant wait‐listing in the era of direct‐acting antiviral therapy , 2017, Hepatology.

[5]  A. Gasbarrini,et al.  Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon , 2017, Alimentary pharmacology & therapeutics.

[6]  M. Colombo,et al.  Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. , 2016, Journal of hepatology.

[7]  J. Vauthey,et al.  Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment. , 2016, Journal of hepatology.

[8]  G. Cabibbo,et al.  Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing. , 2016, Journal of hepatology.

[9]  L. Bolondi,et al.  Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. , 2016, Journal of hepatology.

[10]  A. Walker,et al.  Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. , 2016, Journal of hepatology.

[11]  J. Bruix,et al.  Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. , 2016, Journal of hepatology.

[12]  R. Facchetti,et al.  Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. , 2016, Journal of hepatology.

[13]  G. Cabibbo,et al.  Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension. , 2016, Gastroenterology.

[14]  S. Pol.  Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. , 2016, Journal of hepatology.

[15]  J. Bruix,et al.  Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. , 2016, Gastroenterology.

[16]  R. Sacco,et al.  The calm before the storm: a report from the International Liver Cancer Association Congress 2015--part 1. , 2016, Future oncology.

[17]  M. Makuuchi,et al.  Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. , 2015, The Lancet. Oncology.

[18]  T. Greten,et al.  The yin and yang of evasion and immune activation in HCC. , 2015, Journal of hepatology.

[19]  Korea,et al.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma , 2015, Gut and liver.

[20]  V. Mazzaferro,et al.  Early Hepatocellular Carcinoma on the Procrustean Bed of Ablation, Resection, and Transplantation , 2014, Seminars in Liver Disease.

[21]  M. Iavarone,et al.  Role of antiviral treatment for HCC prevention. , 2014, Best practice & research. Clinical gastroenterology.

[22]  R. Bruno,et al.  Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. , 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[23]  Shou-Dong Lee,et al.  Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. , 2009, Journal of hepatology.

[24]  A. Sanyal,et al.  Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis , 2007, The American Journal of Gastroenterology.

[25]  A. Sanyal,et al.  Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. , 2007, The American journal of gastroenterology.

[26]  M. Latteri,et al.  Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. , 2005, Journal of hepatology.

[27]  S. Kawasaki,et al.  Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. , 2003, Journal of hepatology.

[28]  P. Kamath,et al.  A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts , 2000, Hepatology.

[29]  H. Moriwaki,et al.  Prevention of Second Primary Tumors by an Acyclic Retinoid, Polyprenoic Acid, in Patients with Hepatocellular Carcinoma , 1998, Digestion.

[30]  V. Mazzaferro,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[31]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[32]  R. Pugh,et al.  Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.

[33]  M. Ziol,et al.  Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. , 2017, Gastroenterology.

[34]  J. Bruix,et al.  Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution , 2016 .

[35]  A. Dreher.  Modeling Survival Data Extending The Cox Model , 2016 .

[36]  Riccardo Lencioni,et al.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, Journal of hepatology.